Pluri Inc. (PLUR) - Dilution Analysis

10-Q filing | 10.8M shares outstanding

8-K filing: Pluri Inc. entered into a Securities Purchase Agreement with Chutzpah Holdings LP for a private placement offering of 625,000 common shares and warrants to purchase up to 625,000 common shares, with gross proceeds expected to be approximately $2.5 million. ($2.5M proceeds)

10-Q filing | 9.0M shares outstanding

S-3 filing: This prospectus relates to the resale by the selling shareholders identified in this prospectus may offer from time to time up to 3,875,488 of our Common Shares.

10-K filing | 8.2M shares outstanding

10-Q filing | 7.8M shares outstanding

8-K filing: Pluri Inc. completed its acquisition of approximately 71% of the equity in Kokomodo Ltd. for $4.5 million payable in 976,139 of Pluri Inc.'s Common Shares. ($4.5M proceeds)

8-K filing: Pluri Inc. exchanged 976,139 common shares for additional pre-funded warrants with an exercise price of $0.0001 per share.

8-K filing: The Company will pay the Seller an aggregate purchase price of $4.5 million, payable in 976,139 common shares of the Company in exchange for purchased interests of Kokomodo shares. ($4.5M proceeds)

10-Q filing | 7.0M shares outstanding

8-K filing: Pluri Inc. entered into a Securities Purchase Agreement with Merchant Adventure Fund, L.P. for a private placement offering of 759,219 common shares at $4.61 per share, and warrants to purchase up to 45,553 common shares at an exercise price of $5.568 per share, with gross proceeds expected to be approximately $3.5 million. ($3.5M proceeds)

8-K filing: Pluri Inc. entered into a Securities Purchase Agreement for a private placement offering of common shares, pre-funded warrants, and common warrants with Mr. Alejandro Weinstein, with expected gross proceeds of approximately $6.5 million, and also entered into a binding term sheet for the purchase of shares of Kokomodo Ltd. ($6.38M proceeds)

10-Q filing | 5.5M shares outstanding

10-K filing | 5.2M shares outstanding

10-Q filing | 5.2M shares outstanding

8-K filing: Stock split 1-for-8 | Outstanding: 41,428,439 → 5,227,120

10-Q filing | 41.4M shares outstanding

10-Q filing | 41.3M shares outstanding

S-3/A filing: The company may from time to time sell common shares, preferred stock and warrants to purchase common shares, and units of two or more of such securities, in one or more offerings for an aggregate initial offering price of $200,000,000.

10-K filing | 41.4M shares outstanding

S-3 filing: The company may from time to time sell common shares, preferred stock and warrants to purchase common shares, and units of two or more of such securities, in one or more offerings for an aggregate initial offering price of $200,000,000.

S-3 filing: This S-3 filing relates to the resale by selling shareholders of up to 16,311,800 common shares, consisting of 8,155,900 common shares and warrants to purchase up to an aggregate of 8,155,900 common shares.

10-Q filing | 41.1M shares outstanding

10-Q filing | 39.8M shares outstanding

8-K filing: Pluri Inc. executed Securities Purchase Agreements for a private placement offering of 8,020,900 common shares and warrants to purchase up to 8,020,900 common shares between December 13, 2022, and December 19, 2022.

10-Q filing | 32.6M shares outstanding

10-K filing | 32.2M shares outstanding

10-Q filing | 32.3M shares outstanding

8-K filing: Pluristem Therapeutics Inc. announced the closing of agreements to establish a joint venture company, Plurinuva Ltd., for developing cultured meat products, and Tnuva purchased 187,500 of NewCo's ordinary shares and a warrant for $7,500,000. ($7.5M proceeds)

10-Q filing | 32.2M shares outstanding

8-K filing: Pluristem Therapeutics, Inc. entered into agreements through its subsidiary Pluristem Ltd. with Tnuva Food Industries to establish and operate a joint venture company, Plurinuva Ltd., for developing cultured meat products. ($7.5M proceeds)

10-Q filing | 32.1M shares outstanding

10-K filing | 32.0M shares outstanding

10-Q filing | 31.7M shares outstanding

10-Q filing | 31.5M shares outstanding

8-K filing: Pluristem Therapeutics Inc. entered into a securities purchase agreement to issue and sell 4,761,905 shares of common stock at $6.30 per share in a registered direct offering, for gross proceeds of approximately $30 million, with the closing expected on February 4, 2021. ($30.0M proceeds)

10-Q filing | 25.6M shares outstanding

10-K filing | 25.6M shares outstanding

S-3 filing: The company is filing an S-3 to register the offering of common stock, preferred stock and warrants to purchase common stock, and units of two or more of such securities, in one or more offerings for an aggregate initial offering price of $250,000,000.

10-Q filing | 24.9M shares outstanding

8-K filing: Pluristem Therapeutics Inc. entered into a securities purchase agreement with two institutional investors to issue and sell 1,587,302 shares of common stock at a price of $9.45 per share, with net proceeds expected to be approximately $15,000,000. ($15.0M proceeds)

10-Q filing | 16.9M shares outstanding